- Home
- GHM vs XNCR Comparison
GHM vs XNCR Comparison
Compare GHM & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GHM | XNCR |
|---|---|---|
| Founded | 1936 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.3M | 881.9M |
| IPO Year | 1994 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GHM | XNCR |
|---|---|---|
| Price | $83.91 | $12.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $73.33 | $22.89 |
| AVG Volume (30 Days) | 91.3K | ★ 741.6K |
| Earning Date | 02-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 164.29 | 65.36 |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $209,896,000.00 | $125,576,000.00 |
| Revenue This Year | $14.79 | N/A |
| Revenue Next Year | $17.81 | $11.88 |
| P/E Ratio | $84.43 | ★ N/A |
| Revenue Growth | 13.13 | ★ 13.65 |
| 52 Week Low | $24.78 | $6.92 |
| 52 Week High | $91.91 | $18.69 |
Technical Indicators
Market Signals| Indicator | GHM | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 54.20 | 51.02 |
| Support Level | $47.23 | $10.92 |
| Resistance Level | $90.06 | $12.87 |
| Average True Range (ATR) | 4.68 | 0.69 |
| MACD | -0.47 | 0.07 |
| Stochastic Oscillator | 54.85 | 64.64 |
Price Performance
Historical ComparisonAbout GHM Graham Corporation
Graham Corporation designs and manufactures mission-critical fluid, power, heat transfer, and vacuum technologies for the defense, space, energy, and process industries. The company also services and sells spare parts for its equipment. It designs and manufactures custom-engineered vacuum, heat transfer, cryogenic pump and turbomachinery technologies.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.